Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07447986) titled 'To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Condition:
Systemic Lupus Erythematosus (SLE)
Intervention:
Drug: SG301 SC Injection
Drug: SG301 SC Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 15, 2026
Target Sample Size: 120
Countries of Recruitment:
China...